A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Copper-gluconate/disulfiram (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Dec 2018 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 21 Dec 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
- 21 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Feb 2019.